REMARKS

Reconsideration is requested.

Substitute paper and computer readable forms of the Sequence Listing are being submitted herewith in response to the requirement to comply with the Sequence Rules 37 CFR § 1.821 et seq. The attached substitute paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. Prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.

No new matter is added by the amendments because only sequence identifiers have been added to the specification.

Applicants submit the claims are in condition for allowance and earnestly solicit early Notice to that effect. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

Gary R. Tanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

APPENDIX

MARKED-UP VERSION TO SHOW CHANGES

IN THE SPECIFICATION

Page 18, paragraph starting on line 6,

CAGA boxes containing oligonucleotides (SEQ ID NOS:6-9, respectively):

Page 18, paragraph starting on line 11,

CAGA mutant oligonucleotide (SEQ ID NOS:10-11, respectively):

Page 20, paragraph starting on line 15,

Oligonucleotides were end-labeled with [α-^{33}P]dCTP and [α-^{33}P]dATP using the Klenow fragment of DNA polymerase. Binding reactions containing 10 µg of nuclear extracts or 400 ng of GST-Smad proteins or 16 µL of *in vitro* translated Smad proteins and 2 ng of labeled oligonucleotides were performed for 20 min at 37°C in 18 µL of binding buffer (20 mM HEPES pH 7.9, 30 mM KCl, 4 mM $MgCl_2$, 0.1 mM EDTA, 0.8 mM NaPi, 20% glycerol, 4 mM spermidine, 3 µg poly dI-dC). Protein-DNA complexes were resolved in 5% polyacrylamide gels containing 0.5x TBE. The sequence of the double stranded oligonucleotide (SEQ ID NOS:12-13, respectively) used as a probe was:

Page 20, paragraph starting on line 26,

The sequence of the competitor CAGA mutant oligonucleotide (SEQ ID NOS:14-15, respectively) was:

Page 21, paragraph starting on line 2,

Competitor oligonucleotides (SEQ ID NOS:16-23, respectively) containing other transcription binding sites are:

IN THE SEQUENCE LISTING

Substitute paper and computer readable copies of the Sequence Listing are attached.